2,5,6-Trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: Search for antihyperlipidemic agents

A novel series of 2,5,6-trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles 4(a–d) and 7(a–i) were rationally designed through QSAR based pharmacophore approach and synthesized from 5-(1,3-benzodioxol-5-yl)-[1,3,4]thiadiazol-2-amine (1). The structures of these compounds were established by IR, 1H NMR, 13C NMR, HRMS technique. All the compounds were evaluated for their in vitro antihyperlipidemic activity using trition induced hyperlipidemic model. The newly synthesized title compound 7d, 7e and 7h showed a significant decrease in the serum, TCH, TG LDL and VLDL values along with an increase in serum HDL levels as compared to standard drug Fenofibrate. The treated groups also showed significant decrease in the atherogenic index, LDL:HDL risk ratios and the level of SGOT, SGPT and ALP activities compared to cholesterol induced hyperlipidemic control group. In the present study synthesis and in vitro antihyperlipidemic activity of a novel phenylimidazo[2,1-b][1,3,4]thiadiazole derivatives were evaluated. [Display omitted] •Synthesis and in vitro antihyperlipidemic activity of a novel phenylimidazo[2,1-b][1,3,4]thiadiazole derivatives were evaluated.•Characterized by IR, 1H NMR, 13C NMR, HRMS technique.•The title compound 7d, 7e and 7h shown promising antihyperlipidemic activity.